Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação

Detalhes bibliográficos
Autor(a) principal: Ianiski, Lara Baccarin
Data de Publicação: 2020
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Manancial - Repositório Digital da UFSM
Texto Completo: http://repositorio.ufsm.br/handle/1/21065
Resumo: Pythium insidiosum, belonging to the Kingdom Stramenopila (super group Stramenopiles- Alveolata-Rhizaria - SAR), Class Oomycetes, Order Pythiales, Family Pythiaceae, Genus Pythium and Species Pythium insidiosum is the etiological agent of pythiosis, a chronic granulomatous disease, usually fatal, capable of infecting animals and humans. It is occurring in tropical, subtropical, and temperate areas. Pythiosis is commonly reported in humans in Southeast Asia, mainly in Thailand. Conversely, in Brazil, pythiosis affects mostly equines and it is more prevalent in Pantanal Mato-Grossense and Rio Grande do Sul. This oomycete has characteristics that distinguish it from fungi, especially the incomplete ergosterol biosynthesis pathway, the main target of action of existing antifungal drugs, making it less susceptible to commercially available chemotherapeutic therapies. In an attempt to establish an efficient therapeutic protocol for the control of this disease, therapeutic possibilities to combat infections by P. insidiosum have been widely evaluated. Thus, this study evaluated the in vitro susceptibility profile of P. insidiosum isolates (n = 20) against amorolfine hydrochloride (AMR) and azithromycin (AZM) alone and in combination. The susceptibility tests were performed according to CLSI protocol M38-A2 and the combinations were evaluated by the checkerboard microdilution method. In addition, scanning electron microscopy and transmittance were performed in order to verify the effects on the isolates treated with the drugs. All P. insidiosum isolates evaluated showed minimum inhibitory concentration (MIC) ranging from 16 to 64 mg/L when using AMR and from 8 to 64 mg/L for AZM. Synergistic interactions were not observed, showing 59.8% antagonism and 36.2% indifferent interactions. The scanning electron microscopy and transmittance analyzes showed changes in the surface of the hyphae of P. insidiosum, disorganization of the intracellular organelles, as well as changes in the plasma membrane and cell wall when the microorganism was treated with both drugs. The use of drugs alone presented significant therapeutic potential for the treatment of pythiosis. This is the first study to demonstrate the in vitro activity of AMR, as well as to evaluate its combination with AZM against P. insidiosum. Thus, this drug may represent a therapeutic potential to be further investigated against cutaneous and subcutaneous forms of pythiosis.
id UFSM_f79974707211f2764b580286cc3580d9
oai_identifier_str oai:repositorio.ufsm.br:1/21065
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinaçãoIn vitro Anti-Pythium insidiosum activity of amorolfine hydrochloride and azithromycin, alone and in combinationOomicetoPitioseSuscetibilidadeAmorolfinaAzitromicinaTratamentoOomycetePythiosisSusceptibilityAmorolfineAzithromycinTreatmentCNPQ::CIENCIAS DA SAUDE::FARMACIAPythium insidiosum, belonging to the Kingdom Stramenopila (super group Stramenopiles- Alveolata-Rhizaria - SAR), Class Oomycetes, Order Pythiales, Family Pythiaceae, Genus Pythium and Species Pythium insidiosum is the etiological agent of pythiosis, a chronic granulomatous disease, usually fatal, capable of infecting animals and humans. It is occurring in tropical, subtropical, and temperate areas. Pythiosis is commonly reported in humans in Southeast Asia, mainly in Thailand. Conversely, in Brazil, pythiosis affects mostly equines and it is more prevalent in Pantanal Mato-Grossense and Rio Grande do Sul. This oomycete has characteristics that distinguish it from fungi, especially the incomplete ergosterol biosynthesis pathway, the main target of action of existing antifungal drugs, making it less susceptible to commercially available chemotherapeutic therapies. In an attempt to establish an efficient therapeutic protocol for the control of this disease, therapeutic possibilities to combat infections by P. insidiosum have been widely evaluated. Thus, this study evaluated the in vitro susceptibility profile of P. insidiosum isolates (n = 20) against amorolfine hydrochloride (AMR) and azithromycin (AZM) alone and in combination. The susceptibility tests were performed according to CLSI protocol M38-A2 and the combinations were evaluated by the checkerboard microdilution method. In addition, scanning electron microscopy and transmittance were performed in order to verify the effects on the isolates treated with the drugs. All P. insidiosum isolates evaluated showed minimum inhibitory concentration (MIC) ranging from 16 to 64 mg/L when using AMR and from 8 to 64 mg/L for AZM. Synergistic interactions were not observed, showing 59.8% antagonism and 36.2% indifferent interactions. The scanning electron microscopy and transmittance analyzes showed changes in the surface of the hyphae of P. insidiosum, disorganization of the intracellular organelles, as well as changes in the plasma membrane and cell wall when the microorganism was treated with both drugs. The use of drugs alone presented significant therapeutic potential for the treatment of pythiosis. This is the first study to demonstrate the in vitro activity of AMR, as well as to evaluate its combination with AZM against P. insidiosum. Thus, this drug may represent a therapeutic potential to be further investigated against cutaneous and subcutaneous forms of pythiosis.Pythium insidiosum, pertence ao Reino Stramenopila (super grupo Stramenopiles-Alveolata- Rhizaria - SAR), Classe Oomycetes, Ordem Pythiales, Família Pythiaceae, Gênero Pythium e Espécie Pythium insidiosum é o agente etiológico da pitiose, doença granulomatosa crônica, geralmente fatal, com capacidade de infectar animais e seres humanos. Prevalente em áreas tropicais, subtropicais e temperadas, a pitiose é comumente relatada em seres humanos no sudeste da Ásia, principalmente na Tailândia. Entretanto, no Brasil, a pitiose tem maior ocorrência no Pantanal Mato-Grossense e no Rio Grande do Sul, sendo a espécie equina a mais acometida. Este oomiceto apresenta características que o distingue dos fungos, especialmente a via de biossíntese de ergosterol incompleta, principal alvo de ação de fármacos antifúngicos existentes, tornando-o pouco suscetível as terapias quimioterápicas comercialmente disponíveis. Na tentativa de estabelecer um protocolo terapêutico eficiente para o controle desta enfermidade, possibilidades terapêuticas visando combater infecções por P. insidiosum vêm sendo amplamente avaliadas. Sendo assim, este estudo, avaliou o perfil de suscetibilidade in vitro de isolados de P. insidiosum (n = 20) frente ao cloridrato de amorolfina (AMR) e à azitromicina (AZM) isoladamente e em combinação. Os testes de suscetibilidade foram realizados de acordo com protocolo M38-A2 do CLSI e as combinações foram avaliadas pelo método de microdiluição checkerboard. Adicionalmente, realizou-se microscopia eletrônica de varredura e transmitância a fim de verificar os efeitos sobre os isolados tratados com os fármacos. Todos os isolados de P. insidiosum avaliados apresentaram concentração inibitória mínima (CIMs) variando de 16 a 64 mg/L quando utilizado AMR e de 8 a 64 mg/L para AZM. Interações sinérgicas não foram observadas, evidenciando-se 59,8% de antagonismo e 36,2% de interações indiferentes. Nas análises de microscopia eletrônica de varredura e transmitância, evidenciou-se alterações na superfície das hifas de P. insidiosum, desorganização das organelas intracelulares, bem como modificações na membrana plasmática e na parede celular quando o micro-organismo foi tratado com ambos os fármacos. O uso dos fármacos isoladamente apresentou um potencial terapêutico significativo para o tratamento da pitiose. Este é o primeiro estudo a demonstrar a atividade in vitro da AMR, bem como avaliar sua combinação com AZM frente a P. insidiosum. Desta forma, este fármaco pode representar um potencial terapêutico a ser futuramente pesquisado contra formas cutâneas e subcutâneas de pitiose.Universidade Federal de Santa MariaBrasilFarmáciaUFSMPrograma de Pós-Graduação em Ciências FarmacêuticasCentro de Ciências da SaúdeBotton, Sônia de Avilahttp://lattes.cnpq.br/1177504021154172Pereira, Daniela Isabel BrayerWeiblen, CarlaIaniski, Lara Baccarin2021-06-07T18:38:43Z2021-06-07T18:38:43Z2020-08-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/21065porAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2022-10-07T19:03:15Zoai:repositorio.ufsm.br:1/21065Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2022-10-07T19:03:15Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
In vitro Anti-Pythium insidiosum activity of amorolfine hydrochloride and azithromycin, alone and in combination
title Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
spellingShingle Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
Ianiski, Lara Baccarin
Oomiceto
Pitiose
Suscetibilidade
Amorolfina
Azitromicina
Tratamento
Oomycete
Pythiosis
Susceptibility
Amorolfine
Azithromycin
Treatment
CNPQ::CIENCIAS DA SAUDE::FARMACIA
title_short Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
title_full Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
title_fullStr Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
title_full_unstemmed Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
title_sort Atividade in vitro Anti-Pythium insidiosum do cloridrato de amorolfina e azitromicina isoladamente e em combinação
author Ianiski, Lara Baccarin
author_facet Ianiski, Lara Baccarin
author_role author
dc.contributor.none.fl_str_mv Botton, Sônia de Avila
http://lattes.cnpq.br/1177504021154172
Pereira, Daniela Isabel Brayer
Weiblen, Carla
dc.contributor.author.fl_str_mv Ianiski, Lara Baccarin
dc.subject.por.fl_str_mv Oomiceto
Pitiose
Suscetibilidade
Amorolfina
Azitromicina
Tratamento
Oomycete
Pythiosis
Susceptibility
Amorolfine
Azithromycin
Treatment
CNPQ::CIENCIAS DA SAUDE::FARMACIA
topic Oomiceto
Pitiose
Suscetibilidade
Amorolfina
Azitromicina
Tratamento
Oomycete
Pythiosis
Susceptibility
Amorolfine
Azithromycin
Treatment
CNPQ::CIENCIAS DA SAUDE::FARMACIA
description Pythium insidiosum, belonging to the Kingdom Stramenopila (super group Stramenopiles- Alveolata-Rhizaria - SAR), Class Oomycetes, Order Pythiales, Family Pythiaceae, Genus Pythium and Species Pythium insidiosum is the etiological agent of pythiosis, a chronic granulomatous disease, usually fatal, capable of infecting animals and humans. It is occurring in tropical, subtropical, and temperate areas. Pythiosis is commonly reported in humans in Southeast Asia, mainly in Thailand. Conversely, in Brazil, pythiosis affects mostly equines and it is more prevalent in Pantanal Mato-Grossense and Rio Grande do Sul. This oomycete has characteristics that distinguish it from fungi, especially the incomplete ergosterol biosynthesis pathway, the main target of action of existing antifungal drugs, making it less susceptible to commercially available chemotherapeutic therapies. In an attempt to establish an efficient therapeutic protocol for the control of this disease, therapeutic possibilities to combat infections by P. insidiosum have been widely evaluated. Thus, this study evaluated the in vitro susceptibility profile of P. insidiosum isolates (n = 20) against amorolfine hydrochloride (AMR) and azithromycin (AZM) alone and in combination. The susceptibility tests were performed according to CLSI protocol M38-A2 and the combinations were evaluated by the checkerboard microdilution method. In addition, scanning electron microscopy and transmittance were performed in order to verify the effects on the isolates treated with the drugs. All P. insidiosum isolates evaluated showed minimum inhibitory concentration (MIC) ranging from 16 to 64 mg/L when using AMR and from 8 to 64 mg/L for AZM. Synergistic interactions were not observed, showing 59.8% antagonism and 36.2% indifferent interactions. The scanning electron microscopy and transmittance analyzes showed changes in the surface of the hyphae of P. insidiosum, disorganization of the intracellular organelles, as well as changes in the plasma membrane and cell wall when the microorganism was treated with both drugs. The use of drugs alone presented significant therapeutic potential for the treatment of pythiosis. This is the first study to demonstrate the in vitro activity of AMR, as well as to evaluate its combination with AZM against P. insidiosum. Thus, this drug may represent a therapeutic potential to be further investigated against cutaneous and subcutaneous forms of pythiosis.
publishDate 2020
dc.date.none.fl_str_mv 2020-08-28
2021-06-07T18:38:43Z
2021-06-07T18:38:43Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/21065
url http://repositorio.ufsm.br/handle/1/21065
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmácia
UFSM
Programa de Pós-Graduação em Ciências Farmacêuticas
Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmácia
UFSM
Programa de Pós-Graduação em Ciências Farmacêuticas
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1805922041103122432